Foundation Executive Vice President for Medical Affairs Quoted in NY Times
| 1 min read

A story this week in the New York Times discusses the need for an alternative to pig-derived pancreatic enzyme supplements for cystic fibrosis patients. It highlights the Foundation's collaboration with Altus Pharmaceuticals to develop a synthetic, non-animal derived product.

Preston W. Campbell, III, M.D., executive vice president for medical affairs of the Cystic Fibrosis Foundation, says in the article that if a problem developed in the pig population and resulted in a recall of enzymes, it could be a serious health threat for  people with CF. That's why the Foundation is proactively pursuing a synthetic alternative, he said.

Read the full story.

Share this article
Topics
About the CF Foundation | Medications | Drug Pipeline
Recent news
CF Foundation Awards $1.6 Million to Improve Detection of Lung Transplant Complication
News | 5 min read
CF Foundation Announces New National Advocacy Chairs
News | 5 min read
More Than 160 Advocates Raise Their Voices for PASTEUR Act During March on the Hill
News | 3 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.

Subscribe